Targeting MICA with therapeutic antibodies for the treatment of cancer

Cécile Bonnafous; Valentine Péri; Sylvia Trichard; Ivan Perrot; Stéphanie Cornen; Ariane Thielens; Violette Breso; Yannis Morel; Benjamín Rossi; Carine Paturel; Laurent Gauthier; Mathieu Bléry

doi:10.1186/2051-1426-1-s1-p41

Targeting MICA with therapeutic antibodies for the treatment of cancer

Cécile Bonnafous(Innate Pharma (France)), Valentine Péri(Innate Pharma (France)), Sylvia Trichard(Innate Pharma (France)), Ivan Perrot(Innate Pharma (France)), Stéphanie Cornen(Innate Pharma (France)), Ariane Thielens(Innate Pharma (France)), Violette Breso(Innate Pharma (France)), Yannis Morel(Innate Pharma (France)), Benjamín Rossi(Innate Pharma (France)), Carine Paturel(Innate Pharma (France)), Laurent Gauthier(Innate Pharma (France)), Mathieu Bléry(Innate Pharma (France))

Journal for ImmunoTherapy of Cancer

January 1, 2013

10.1186/2051-1426-1-s1-p41

Cited by 5Open Access

Full Text

Abstract

Meeting abstracts MICA and MICB, along with ULPBs, are ligands for the activating receptor NKG2D expressed on NK cells and subsets of T cells in Human. NKG2D ligands are induced by cellular stress and pathogen infections. Their expression is tightly regulated by complex mechanisms both at the mRNA

Related Papers

No related papers found

Powered by citation graph analysis